Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings, Inc. (SNCE) is frequently featured in clinical research news for its role in expanding patient access to trials through virtual and direct-to-patient models. Company announcements highlight its Metasite™ Virtual Site, Direct-to-Patient Site, and Patient Recruitment solutions, which are used by clinical trial sponsors and CROs to address enrollment and study conduct challenges across a range of therapeutic areas.
News about Science 37 often focuses on its participation in Phase 2 and Phase 3 studies, including rare disease, asthma, infectious disease, and immunocompromised patient cohorts. The company has reported contributing significant portions of total enrollment in pivotal trials, as well as helping under-enrolling studies trend back toward projected recruitment targets. These updates provide insight into how its decentralized and virtual site models function in real-world clinical programs.
Another recurring theme in Science 37 news is regulatory oversight and quality. The company has disclosed multiple FDA inspections of its Metasite™ and Direct-to-Patient Site models, with outcomes described as No Action Indicated and no Form 483s issued. Coverage of these inspections details how regulators have reviewed internal processes, technology platforms, data integrity, subject safety, and Principal Investigator oversight.
Investors and industry observers following SNCE news can expect updates on new partnerships with sponsors and service providers, case studies on enrollment performance, and developments related to its headquarters and operational footprint in Morrisville, North Carolina. This news stream offers context on how Science 37’s virtual and direct-to-patient approaches are being applied across different studies and therapeutic areas.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has appointed Michael Shipton as Chief Commercial Officer to enhance business development and capitalize on the demand for decentralized clinical trials. With over 25 years of experience in clinical research, including significant sales achievements at Syneos Health, Shipton aims to drive enterprise growth and improve clinical trial accessibility. CEO David Coman emphasizes Shipton's expertise as critical for meeting ambitious growth goals. The company, known for its Agile Clinical Trial Operating System, seeks to streamline research processes for patients and providers.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced its participation in the Baird Global Healthcare Conference in New York, scheduled for September 13, 2022, at 3:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the company's Investor Relations webpage.
Science 37 aims to improve access to clinical research through its Agile Clinical Trial Operating System™, enhancing the speed and diversity of patient enrollment while supporting decentralized clinical trials.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has partnered with NuvoAir to enhance clinical trials by integrating remote respiratory endpoint data collection. This collaboration allows patients to participate in trials without needing to visit hospitals, significantly reducing patient burden. Utilizing a variety of connected devices and software, the solution aims to improve trial accessibility and diversity, achieving up to 21x faster patient enrollment and 28% better retention. With 3,781 active respiratory trials, the partnership is set to streamline trial processes and enhance patient experience.
Science 37 Holdings has introduced new patient relationship management and contact center technologies aimed at enhancing patient engagement for clinical trials. This initiative is expected to improve patient recruitment efficiency, leading to faster and more qualified enrollment. The new platform is designed to facilitate real-time communication between patients and study coordinators, addressing the challenges of traditional clinical trial participation. Importantly, Science 37 aims to eliminate geographic barriers, ultimately enhancing access to clinical research.
Science 37 Holdings (Nasdaq: SNCE) has partnered with Syapse to improve patient recruitment for oncology clinical trials through real-world data analytics. This collaboration aims to address the significant enrollment delays—often costing trial sponsors over $20 million monthly—by leveraging Syapse's patient identification capabilities and Science 37's agile trial systems. With over 3,700 active oncology trials globally and R&D spending projected at $70 billion in 2022, this partnership could enhance trial efficiency and accelerate access to new treatments for patients in need.
Science 37 Holdings, Inc. (SNCE) reported a 54% year-over-year increase in revenue for Q2 2022, totaling $19.3 million. However, net bookings decreased to $25.4 million from $44.1 million year-over-year. The adjusted gross profit rose slightly to $5.9 million, with an adjusted gross margin of 30.6%. The net loss was $5.8 million, improving from a $7.7 million loss in the prior year. The company estimates full-year revenue between $76 million and $86 million, and adjusted EBITDA guidance of $(65) million to $(69) million.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announces it will release its second quarter 2022 financial results on August 11, 2022, before the market opens. The company's management will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Participants can access the call by registering online for dial-in information or through a live audio webcast. A replay will be available shortly after the call and will remain accessible for approximately 90 days.
Summary not available.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will participate in two major virtual investor conferences this June. The first is the Lytham Partners Summer 2022 Investor Conference from June 21-22, where a presentation will be available starting June 21 at 9:00 a.m. Eastern Time. The second event is the Cowen 7th Annual FutureHealth Conference on June 23 at 3:25 p.m. Eastern Time, featuring a panel discussion on clinical trial access and affordability. Webcasts can be accessed via the company's Investor Relations page.
Science 37 Holdings (Nasdaq: SNCE) will present at the William Blair Growth Stock Conference in Chicago on June 8, 2022, at 3:20 p.m. CT. The company aims to enhance participation in clinical trials through its Agile Clinical Trial Operating System, designed for decentralized research. This platform boasts significant advantages, including up to 15x faster enrollment and a 28% increase in patient retention rates, ensuring diverse patient participation. A live and archived webcast of the presentation will be available on the investor relations section of Science 37's website.
